Dr. Bryan Lawlis Joins GlycoFi, Inc. Board Of Directors
10/19/2005 5:13:01 PM
LEBANON, N.H.--(BUSINESS WIRE)--March 16, 2005--GlycoFi, Inc., a privately-held biotechnology company, is pleased to announce today that it has appointed V. Bryan Lawlis, Ph.D., President and CEO of Aradigm Corporation to its Board of Directors. Dr. Lawlis, a 25-year biotech industry veteran, brings his broad experience in therapeutic protein development and manufacturing, to strengthen GlycoFi's Board as its first outside Director.
At Aradigm, Dr. Lawlis has served as President and Chief Executive Officer since August 2004, as President and Operating Officer from June 2003 to August 2004 and as Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman 1999 to 2001, when it was sold to Diosynth, a division of Akzo Nobel. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences.